Literature DB >> 17851555

Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status.

A Cortelezzi, G Gritti, N Del Papa, M C Pasquini, R Calori, U Gianelli, M Cortiana, G Parati, F Onida, F Sozzi, C Vener, P Bianchi, G L Deliliers.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17851555     DOI： 10.1038/sj.leu.2404943

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Authors:  A Tabarroki; D J Lindner; V Visconte; L Zhang; H J Rogers; Y Parker; H K Duong; A Lichtin; M E Kalaycio; M A Sekeres; S E Mountantonakis; G A Heresi; R V Tiu
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

2.  Pulmonary arterial hypertension exacerbated by ruxolitinib.

Authors:  Andrew T Low; Luke Howard; Claire Harrison; Robert M R Tulloh
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

3.  Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms.

Authors:  Emir C Roach; Margaret M Park; W H Wilson Tang; James D Thomas; Kewal Asosingh; Matt Kalaycio; Serpil C Erzurum; Samar Farha
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

Review 4.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 5.  Drug-induced pulmonary arterial hypertension: a review.

Authors:  Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

6.  Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.

Authors:  Matthew Austin; Peter J Quesenberry; Corey E Ventetuolo; Olin Liang; John L Reagan
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-05-13

7.  Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.

Authors:  Orly Leiva; Siyang Ren; Donna Neuberg; Ankeet Bhatt; Andrew Jenkins; Rachel Rosovsky; Rebecca Karp Leaf; Katayoon Goodarzi; Gabriela Hobbs
Journal:  Int J Hematol       Date:  2022-10-02       Impact factor: 2.319

Review 8.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

9.  Platelets in pulmonary vascular physiology and pathology.

Authors:  Michael H Kroll; Vahid Afshar-Kharghan
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

Review 10.  The Role of JAK/STAT Molecular Pathway in Vascular Remodeling Associated with Pulmonary Hypertension.

Authors:  Inés Roger; Javier Milara; Paula Montero; Julio Cortijo
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.